China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
Recent Articles
RECENT ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK 47.40 (+2.2%) -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK 47.40 (+2.2%)
